CJC-1295 raised growth hormone for days, and the natural pulse pattern survived the continuous stimulation.

The CJC-1295 finding that organizes this digest

CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH). In healthy young men, a single subcutaneous dose raised trough growth hormone roughly 7.5-fold and IGF-1 by about 45% one week later — and the frequency and magnitude of pulsatile GH secretion were unaltered ^[1]. That last clause is the lead of this curated digest. A drug can elevate a hormone for days without flattening the body's own rhythm, and CJC-1295 is one of the clearest demonstrations of it on the record.

The rest of the page ranks the evidence the way a magazine ranks stories: the biggest card is the GH pulsatility result; the tall secondary card is the DAC-versus-no-DAC half-life split; the smaller tiles are the mechanism and the synergy rationale. Each card carries its study. None of it sells anything — the negative space here is editorial, not a checkout.

The compound itself is built on the first 29 residues of human GH-releasing factor, hGRF(1-29), with four amino-acid substitutions that block enzymatic cleavage ^[2]. In the long-acting DAC variant, a chemical linker binds the peptide covalently to circulating serum albumin, stretching the plasma half-life to an estimated 5.8-8.1 days ^[3]. The short-acting no-DAC form, often labeled 'Modified GRF 1-29,' keeps the substitutions but drops the albumin handle. Conflating the two is the single most common error in how CJC-1295 is discussed — the CJC-1295 DAC vs no-DAC page is built to keep them apart.

Does CJC-1295 preserve the natural pulse pattern of growth hormone?

Yes, on the available human evidence. In healthy 20-to-40-year-old men, a single subcutaneous dose of CJC-1295 (60 or 90 micrograms/kg) raised basal GH approximately 7.5-fold and IGF-1 by about 45% one week later, while the frequency and amplitude of pulsatile GH secretion stayed unchanged ^[1]. The interpretation: pulsatility can persist even under continuous GHRH-analog stimulation.

This matters because pulsatility is not cosmetic. Episodic GHRH delivery is more effective than continuous infusion at driving GH pulses in humans ^[7], so a long-acting analog that elevates baseline output without erasing the pulse pattern is a more biologically interesting result than a simple 'GH goes up' headline. A 2025 study mapping a neuroendocrine circuit for sleep-dependent GH release underscores how tightly the body gates its own pulses ^[15] — context for why a preserved rhythm is worth surfacing first.

CJC-1295 as a GHRH-Analog Peptide

CJC-1295 is a peptide, not a hormone replacement and not a steroid. As a GHRH-analog peptide it binds the GHRH receptor — a class-B G-protein-coupled receptor on anterior-pituitary somatotrophs — and activates Gs/cAMP/PKA signaling that drives GH synthesis and release ^[2]. The released GH then raises hepatic IGF-1 through the GH receptor and JAK2/STAT5 ^[3]. So CJC-1295 sits one step upstream of growth hormone: it tells the pituitary to make and release more of its own GH rather than supplying GH directly.

The four substitutions on the hGRF(1-29) backbone — D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27 — stabilize the helix and block dipeptidylpeptidase-IV cleavage, deamidation, and oxidation, the three routes that clear native GHRH within minutes ^[2]. That protease resistance is what makes a multi-day analog possible at all; the DAC albumin conjugation is what extends it from hours to days. The molecule's identity is well characterized: CAS 863288-34-0, PubChem CID 91971820, a molar mass near 3367.9 Da for the DAC peptide before it conjugates to albumin.

Because CJC-1295 acts upstream, its effect is shaped by the pituitary it acts on rather than overriding it. That is the structural reason the body's own feedback and rhythm survive — the somatotroph still releases GH in pulses; the analog raises the baseline those pulses ride on. The result reads as 'more of your own GH, on your own schedule' rather than a flat exogenous flood.

What does CJC-1295 do?

It binds the GHRH receptor on pituitary somatotrophs, stimulating synthesis and pulsatile release of growth hormone, which in turn raises hepatic IGF-1 ^[2][3]. In healthy adults, a single DAC dose elevated GH and IGF-1 for days ^[3], and the natural GH pulse pattern was preserved ^[1]. In short: it amplifies the GH/IGF-1 axis the body already runs, rather than replacing it.

What is CJC-1295?

A synthetic long-acting analog of growth-hormone-releasing hormone built on hGRF(1-29) with four protease-resistant substitutions ^[2]. The DAC variant adds covalent serum-albumin conjugation for a multi-day half-life ^[3], while the no-DAC form ('Modified GRF 1-29') is short-acting. It is a single research peptide, not a blend, and it is not approved for human use.

What this site is, and what it is not

This is a curated reading of published CJC-1295 research, arranged so the strongest findings sit largest. It is not a clinic, not a pharmacy, and not a storefront. CJC-1295 is an unapproved research chemical — not approved for human use by the FDA or any major regulator, and prohibited at all times in sport under WADA Section S2. It circulates outside the clinic: CJC-1295 was identified by LC-MS/MS as the active ingredient in an unknown 'GHRH' preparation seized in an anti-doping context ^[6]. We report what studies measured, in which species, at which doses; we make no human-use recommendation.

From here, the digest fans out: the GH/IGF-1 axis findings on the research page, the doses used in the research on the dosage page, the CJC-1295 and ipamorelin synergy lens, the DAC-versus-no-DAC pharmacokinetics, the reported concerns and safety on the FAQ, the regulatory status summary, and the full reference list.